Research Article
A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type?
Table 5
Mean optical density of elastogenesis and degradation markers in anetoderma.
| Group | Disease duration | Epidermis | Dermis | Elastin | Fibrillin | MMP-2 | MMP-9 | TIMP-1 | Elastin | Fibrillin | MMP-2 | MMP-9 | TIMP-1 |
| Case 1, (protruding lesion) | 12 months | 0.00 | 71.87 ± 4.16 | 130.96 ± 13.05 | 104.23 ± 4.88 | 103.10 ± 12.71 | 22.54 ± 4.47 | 50.91 ± 3.29 | 88.19 ± 6.66 | 102.66 ± 11.57 | 51.75 ± 14.67 | Control 1 | NA | 0.00 | 108.30 ± 19.12 | 125.98 ± 6.45 | 103.40 ± 6.06 | 81.71 ± 2.07 | 119.46 ± 7.15 | 74.32 ± 10.73 | 45.30 ± 25.72 | 8.63 ± 7.66 | 70.37 ± 13.62 | Case 2, (protruding lesion) | 1 week | 0.00 | 56.16 ± 8.75 | 62.39 ± 10.45 | 107.69 ± 8.14 | 100.27 ± 6.46 | 39.62 ± 5.21 | 19.67 ± 15.86 | 83.16 ± 16.92 | 80.49 ± 7.18 | 42.00 ± 8.08 | Control 2 | NA | 0.00 | 56.68 ± 10.56 | 44.45 ± 25.07 | 100.70 ± 5.78 | 49.29 ± 6.89 | 65.13 ± 33.51 | 25.72 ± 13.25 | 23.26 ± 13.42 | 43.88 ± 8.85 | 25.10 ± 3.25 | Case 3, (indented lesion) | 18.7 months | 0.00 | 88.86 ± 15.5 | 72.08 ± 5.55 | 100.79 ± 7.16 | 95.22 ± 15.34 | 132.99 ± 7.19 | 89.33 ± 43.52 | 32.73 ± 16.18 | 77.28 ± 39.22 | 58.03 ± 4.65 | Control 3 | NA | 0.00 | 99.68 ± 2.81 | 98.22 ± 4.99 | 53.35 ± 18.21 | 114.52 ± 16.75 | 159.44 ± 16.87 | 112.91 ± 57.10 | 125.58 ± 24.57 | 55.27 ± 8.08 | 109.37 ± 6.62 | Normal control | NA | 0.00 | 124.89 ± 5.90 | 92.93 ± 9.45 | 29.29 ± 3.29 | 108.33 ± 11.59 | 148.47 ± 8.33 | 103.03 ± 10.37 | 104.82 ± 13.92 | 72.08 ± 12.39 | 139.56 ± 28.57 |
|
|
NA: not applicable.
|